Tenax Therapeutics (NASDAQ:TENX – Get Free Report) is expected to be issuing its quarterly earnings data before the market ...

Harrington Prize for Innovation in Medicine has been awarded to Owen N. Witte, MD, Distinguished University Professor and President's Chair in Developmental Immunology, David Geffen School of Medicine ...

The lawsuit alleges that JPMorgan breached its fiduciary duties under the Employee Retirement Income Security Act, the law that governs large employers’ benefit plans. The plaintiffs argue that ...

Shorla Oncology (‘Shorla’), a US- Ireland specialty pharmaceutical company headquartered in Clonmel, County Tipperary, has ...

PhD Defense: Advancing Therapeutic Drug Monitoring of oral targeted anticancer drugs; analytical and clinical studies ...

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg. (USRLD: ...

The rise in Biocon share price came after the company announced that its wholly-owned subsidiary, Biocon Pharma, has received final approvals for Lenalidomide capsules and Dasatinib tabs from USFDA ...

Company to Roll Out Availability of IMKELDI (imatinib) for Patients with Certain Forms of Leukemia and Other Cancers Shorla Oncology ('Shorla'), a U.S.-Ireland specialty pharmaceutical company, ...

Discontinuing tyrosine kinase inhibitor maintenance after extended complete molecular response should only be attempted as part of a clinical trial, the researchers say.

We report two cases of large proximal (cardia/fundus) GIST tumours (51 and 60 mm) which were downsized (to 26 and 36 mm) by 3–7 months of imatinib therapy followed by transmural endoscopic resection.

Participants: Chris Giordano, President & Chief Executive Officer, Stuart Rich, MD, Chief Medical Officer The live and archived webcast of the presentation will be accessible from the Company’s ...